Cash and investments at December 31, 2007 totaled $23.7 million, compared with $37.0 million at December 31, 2006. Subsequent to the end of the year, the Company received $20 million in one-year unsecured loan commitments. This, along with funds provided by the Company's working capital facility, provides Stereotaxis with approximately $60 million of liquidity. Total debt at December 31, 2007 was $7.0 million.
Conference Call Information
The Company has scheduled a conference call for 8:30 a.m. Eastern Standard Time today to discuss its financial results for the fourth quarter. To access the conference call, please dial (800) 240-2430. International participants can call (303) 262-2175. An audio replay of the call will be available for seven 7 days following the call at (800) 405-2236 for U.S. callers or (303) 590-3000 for those calling outside the U.S. The password required to access the replay is 11110029#. The call will also be available on the Internet live and for 90 days thereafter at the following URL:
Stereotaxis designs, manufactures and markets an advanced cardiology
instrument control system for use in a hospital's interventional surgical
suite to enhance the treatment of coronary artery disease and arrhythmias.
The Stereotaxis System is designed to enable physicians to complete more
complex interventional procedures by providing image guided delivery of
catheters and guidewires through the blood vessels and chambers of the
heart to treatment sites. This is achieved using computer-controlled,
externally applied magnetic fields that govern the motion of the working
tip of the catheter or guidewire, resulting in improved navigation, shorter
procedure time and reduced x-ray exposure. The core components of the
Stereotaxis system have received regulatory clearance in the U.S., Eu
|SOURCE Stereotaxis, Inc.|
Copyright©2008 PR Newswire.
All rights reserved